Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs

Drug Metabolism and Disposition

Volumn 36, Issue 8, 2008, Pages 1519-1528

  Sjödin, Elin ^a   Fritsch, Holger ^a,d   Eriksson, Ulf G ^c   Logren, Ulrika ^c   Nordgren, Anders ^b   Forsell, Patrik ^b   Knutson, Lars ^b   Lennernäs, Hans ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABBOTICIN; CYTOCHROME P450; ERYTHROMYCIN; ETHYLMELAGATRAN; HYDROXYMELAGATRAN; ISOENZYME; MELAGATRAN; MELAGATRAN ASTRA ZENECA; THROMBIN INHIBITOR; XIMELAGATRAN; XIMELAGATRAN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BILE LEVEL; DRUG DISPOSITION; DRUG LIVER LEVEL; DRUG TRANSPORT; FEMALE; HEPATOBILIARY SYSTEM; INTESTINE ABSORPTION; INTESTINE BLOOD FLOW; INTESTINE PERFUSION; INTRAHEPATIC BILE DUCT; INTRAJEJUNAL DRUG ADMINISTRATION; JEJUNUM; LIVER METABOLISM; LIVER SINUSOID; MALE; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SINGLE DRUG DOSE; SWINE; THROMBOSIS PREVENTION;

ANIMALS; ANTICOAGULANTS; AREA UNDER CURVE; AZETIDINES; BENZYLAMINES; BILIARY TRACT; BIOTRANSFORMATION; INTESTINES; LIVER; SWINE;

SUIDAE;

EID: 47949090356     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020412     Document Type: Article

References (40)

1. Andersson S, Hofmann Y, Nordling A, Li XQ, Nivelius S, Andersson TB, Ingelman-Sundberg M, and Johansson I (2005) Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime. Drug Metab Dispos 33:570-578.
2. Anzenbacher P, Soucek P, Anzenbacherova E, Gut I, Hruby K, Svoboda Z, and Kvetina J (1998) Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples. Drug Metab Dispos 26:56-59.
3. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, and Eriksson UG (2003) Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 42:765-777.
4. Chui C, Kobayashi E, Chen X, Hisada T, and Sakuma I (2004) Combined compression and elongation experiments and non-linear modelling of liver tissue for surgical simulation. Med Biol Eng Comput 42:787-798.
5. Clement B and Lopian K (2003) Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 31:645-651.
6. Dunér K, Backstrom J, Magnell N, Svennberg H, Ahnoff M, and Logren U (2007) Determination of ximelagatran, melagatran and two intermediary metabolites in plasma by mixed-mode solid phase extraction and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 852:317-324.
7. Eisenblätter T and Galla HJ (2002) A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Commun 293:1273-1278.
8. Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislen K, Fager G, and Gustafsson D (2003) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 31:294-305.
9. Eriksson UG, Dorani H, Karlsson J, Fritsch H, Hoffmann KJ, Olsson L, Sarich TC, Wall U, and Schutzer KM (2006) Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein- mediated excretion. Drug Metab Dispos 34:775-782.
10. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, and Friedberg T (2002) Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64:1569-1578.
11. Greenblatt DJ and von Moltke LL (2005) Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 45:127-132.
12. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, et al. (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101:171-181.
13. Hawkins D (2004) Limitations of traditional anticoagulants. Pharmacotherapy 24:62S-65S.
14. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340.
15. Imai T, Imoto M, Sakamoto H, and Hashimoto M (2005) Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab Dispos 33:1185-1190.
16. Imai T, Taketani M, Shii M, Hosokawa M, and Chiba K (2006) Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 34:1734-1741.
17. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, and Eriksson UG (2003) Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 42:381-392.
18. Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351-380.
19. Knutson L, Odlind B, and Hallgren R (1989) A new technique for segmental jejunal perfusion in man. Am J Gastroenterol 84:1278-1284.
20. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, and Yamamoto T (2005) Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos 33:619-622.
21. Krishnan TR, Abraham I, and Craig S (1994) Use of the domestic pig as a model for oral bioavailability and pharmacokinetic studies. Biopharm Drug Dispos 15:341-346.
22. Lam JL, Okochi H, Huang Y, and Benet LZ (2006) In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34:1336-1344.
23. Larsson M, Ahnoff M, Abrahamsson A, Logren U, Fakt C, Ohrman I, and Persson BA (2003) Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatographymass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 783:335-347.
24. Lennernas H, Ahrenstedt O, Hallgren R, Knutson L, Ryde M, and Paalzow LK (1992) Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 9:1243-1251.
25. Musidlowska-Persson A and Bornscheuer UT (2003) Recombinant porcine intestinal carboxylesterase: cloning from the pig liver esterase gene by site-directed mutagenesis, functional expression and characterization. Protein Eng 16:1139-1145.
26. Nejdfors P, Ekelund M, Jeppsson B, and Westrom BR (2000) Mucosal in vitro permeability in the intestinal tract of the pig, the rat, and man: species- and region-related differences. Scand J Gastroenterol 35:501-507.
27. Nordgren A, Karlsson T, and Wiklund L (2002) Glutamine concentration and tissue exchange with intravenously administered alpha-ketoglutaric acid and ammonium: a dose-response study in the pig. Nutrition 18:496-504.
28. Persson EM, Nordgren A, Forsell P, Knutson L, Ohgren C, Forssen S, Lennernas H, and Abrahamsson B (2008) Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model. Eur J Pharm Sci 34:22-29.
29. Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L, and Lennernas H (2006) First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab Dispos 34:1182-1189.
30. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
31. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493.
32. Schlatter P, Gutmann H, and Drewe J (2006) Primary porcine proximal tubular cells as a model for transepithelial drug transport in human kidney. Eur J Pharm Sci 28:141-154.
33. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, Dorje F, Fromm MF, and Konig J (2007) The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 35:779-786.
34. Sutton SC, Rinaldi MT, and Vukovinsky KE (2001) Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model. AAPS PharmSci 3:E25.
35. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, and Murakami T (1998) Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358:289-294.
36. Tang H, Pak Y, and Mayersohn M (2004) Protein expression pattern of P-glycoprotein along the gastrointestinal tract of the Yucatan micropig. J Biochem Mol Toxicol 18:18-22.
37. Tannergren C, Evilevitch L, Pierzynowski S, Piedra JV, Westrom B, Erlwanger K, Tatara M, and Lennernas H (2006) The effect of pancreatic and biliary depletion on the in vivo pharmacokinetics of digoxin in pigs. Eur J Pharm Sci 29:198-204.
38. Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, Shiozawa K, Nakamura T, Tsukamoto K, Noguchi Y, et al. (2000) Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob Agents Chemother 44:1697-1700.
39. Török M, Huwyler J, Gutmann H, Fricker G, and Drewe J (2003) Modulation of transendothelial permeability and expression of ATP-binding cassette transporters in cultured brain capillary endothelial cells by astrocytic factors and cell-culture conditions. Exp Brain Res 153:356 -365.
40. Zuber R, Anzenbacherova E, and Anzenbacher P (2002) Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189-198.